Eli Lilly is leaning into its obesity and cardiometabolic franchise, reporting detailed Phase 3 results for Foundayo and Zepbound across conditions like obstructive sleep apnea and psoriatic arthritis...
Source LinkEli Lilly is leaning into its obesity and cardiometabolic franchise, reporting detailed Phase 3 results for Foundayo and Zepbound across conditions like obstructive sleep apnea and psoriatic arthritis...
Source Link
Comments